8F8 Stock Chart & Stats
€2.08
€0.06(6.50%)
At close: 4:00 PM EST
€2.08
€0.06(6.50%)
Day’s Range― - ―
52-Week Range€0.97 - €2.32
Previous CloseN/A
Volume0.00
Average Volume (3M)89.00
Market Cap
€95.56M
Enterprise Value€501.49M
Total Cash (Recent Filing)€68.89M
Total Debt (Recent Filing)€1.54M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding53,330,242
10 Day Avg. Volume268
30 Day Avg. Volume89
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance-sheet FlexibilityVery low debt reduces solvency risk and gives management flexibility to fund clinical programs without heavy interest burdens. Over 2-6 months this structural strength lowers refinancing pressure, supporting strategic options like partnerships or milestone financing.
Focused Clinical-stage PipelineA clear lead candidate with a defined mechanism (melanocortin receptor agonist) concentrates R&D efforts and makes milestone outcomes easier to assess. This focused pipeline supports value-creating partnerships or licensing if clinical proof-of-concept is achieved.
Multiple Durable Monetization RoutesThe company can pursue partnering, licensing, collaborations or equity raises to fund development. Having multiple, structural monetization paths reduces dependency on a single outcome and increases the likelihood of securing financing to progress trials over months.
Bears Say
Pre-revenue With Widening LossesAbsence of product revenue and increasing annual losses show reliance on external funding. Widening losses reflect higher development or operating costs and reduce runway absent financing or deals, raising execution and dilution risk over the medium term.
Persistent Negative Cash Flow / Heavy BurnSustained negative operating and free cash flow indicates the company consumes cash faster than it generates, creating continuous funding needs. Ongoing burn increases the probability of near-term capital raises that could dilute investors or force constrained deal terms.
Declining Shareholder Equity / Funding RiskA meaningful decline in equity reduces the balance-sheet buffer and signals accumulated losses or dilutive financings. Even with low debt, shrinking equity elevates funding risk and makes future capital raises likelier, which can limit strategic optionality and increase dilution.
SynAct Pharma AB News
8F8 FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was €0.97 and its highest was €2.32 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is €95.56M.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is Aug 20, 2026 which is in 49 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on May 27, 2026. The company reported -€0.044 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.044.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 53,330,242 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -€0.044 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.789%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in DE:8F8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Technical Analysis
Oncopeptides AB
―
Saniona AB
―
Ascelia Pharma AB
―
Guard Therapeutics International AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---